Market Overview

Tickers

Articles

Keywords

Search by keyword...
googlecse

Quotes

Analysis

Analyst Ratings

News

Press Releases

Twitter

Media Mentions

Ownership

Earnings

Pozen, Inc. (POZN) 8.84 -0.155
Price Open:5.10Day's Range:0.00000 - 6.90000
Price Close:5.1252wk Range:0.00000 - 8.12
Price Day Change:-0.155Volume:78,745
Price % Change:-3.03Market Cap:150.8M
Bid:0.00000PE Ratio:0
Ask:8.84000EPS Diluted:-0.751
Trade POZN NOW!

The Latest On POZN

Stocks Hitting 52-Week Lows 4/5/13 12:41pm
POZEN Submits NDA for PA32540/PA8140 3/27/13 7:32am
European Patent Office Maintains POZEN PA/VIMOVO Patent 3/12/13 7:37am
Zacks Reiterates Outperform Rating, $9.50 PT on POZEN on PA-325/40 Product Data Presentations 3/6/13 3:12pm
Earnings Scheduled For March 6, 2013 3/6/13 5:13am
POZEN to Offer Phase 3 Data on PA32540 at International Stroke Conference 2/8/13 8:34am
UPDATE: Ascendiant Capital Markets Upgrades POZEN to Strong Buy, Reiterates $8.25 PT 11/9/12 1:33pm
UPDATE: Ascendiant Capital Markets Initiates POZEN at Buy; Future Royalties Attractive 10/9/12 12:25pm
POZEN Patents Upheld in Treximet Patent Litigation Appeal 10/1/12 4:26pm
POZEN Announces PA32540 Provides Superior Antiplatlet Effects over a Standard of Care Regimen in a Phase 1 Study ("Co-Rx") 8/29/12 7:32am
POZEN Provides Positive Update on Its PA Program and Results of Its Type A Meeting with the FDA 8/23/12 4:15pm
POZEN Receives Patent on PA Products for Treatment of Cardiovascular Disease and Osteoarthritis 6/26/12 7:30am
more
Press Releases
POZEN Announces FDA Acceptance of Filing of New Drug Application for PA32540/PA8140 Tablets 5/29/13 Business Wire
POZEN to Present at the Jefferies 2013 Global Healthcare Conference 5/23/13 Business Wire
Presence of Gastric Erosions in Patients Taking Low-Dose Aspirin for Secondary Cardiovascular Prevention May Result in a 2-Fold Increase in Future Gastric Ulcers 5/21/13 Business Wire
POZEN Reports First Quarter 2013 Results 5/8/13 Business Wire
POZEN Announces May 8th Webcast of First Quarter 2013 Results 4/30/13 Business Wire
POZEN Announces Results from a Burden of Cardiovascular Disease Study: a Managed Care Perspective 4/5/13 Business Wire
POZEN Submits New Drug Application for PA32540/PA8140 3/27/13 Business Wire
POZEN Reports European Patent Office Maintains PA/VIMOVO Patent 3/12/13 Business Wire
POZEN to Present at the 25th Annual ROTH Conference 3/7/13 Business Wire
POZEN Reports Fourth Quarter & Year End 2012 Results 3/6/13 Business Wire
POZEN Announces March 6th Webcast of Fourth Quarter and Year End 2012 Results 2/27/13 Business Wire
POZEN Presents Positive PA32540 Phase 3 Data at the 2013 International Stroke Conference 2/8/13 Business Wire

Get the latest POZN stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Pozen, Inc. stock price.

Partner Headlines
Pozen Inc. Reports Operating Results (10-Q) 11/9/12
Small Bump In The Road For Pozen's PA - Analyst Blog 6/21/12
Celgene, Bed Bath & Beyond Among Stocks Gapping Down Thursday 6/21/12
Pozen Inc. Reports Operating Results (10-Q) 5/3/12
Health Care Sector Wrap 4/30/12
The Home Depot, Sempra Energy Among Stocks Hitting 52-Week Highs Monday 4/16/12
Pozen Inc. Reports Operating Results (10-Q) 11/3/11
The InterMune Debacle Post-Script
Acadia Pharmaceuticals: Investing With No Safety Net
5 Stocks Under $10 Set to Soar Higher